Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxucosa is an oral dietary supplement marketed by Dong Do Pharmaceutical in Vietnam, primarily categorized as a health protection food (TPBVSK). It is formulated to support joint health and manage symptoms associated with osteoarthritis and other degenerative joint conditions. The product typically contains a combination of glucosamine sulfate and chondroitin sulfate, which are essential structural components of articular cartilage. These ingredients work synergistically to provide the necessary building blocks for cartilage synthesis, improve joint lubrication, and potentially inhibit enzymes that contribute to cartilage degradation, thereby helping to reduce joint pain and improve mobility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Maxucosa.